Bremelanotide (PT-141) Research: What FDA Approval Does—and Does Not—Mean

The short version

Bremelanotide, originally identified in development as PT-141, is a synthetic cyclic melanocortin-receptor agonist. Cell and structural studies show that it can engage several melanocortin receptor subtypes. Animal experiments reported changes in selected sexual behaviors, and a human development program progressed from small exploratory studies to two randomized phase 3 trials.

FDA approved the finished prescription product Vyleesi in 2019 for a narrowly defined population and indication. The two pivotal trials found statistically significant improvements in questionnaire measures of desire and distress, but not in the secondary measure of satisfying sexual events. Approval applies to the reviewed drug-device product, formulation, manufacturing controls, labeling, and intended population. It does not transfer to an online vial labeled ‘PT-141,’ to another formulation, or to broader claims involving men, postmenopausal women, performance enhancement, or general libido.

Are bremelanotide and PT-141 the same compound?

PT-141 is the development code historically used for bremelanotide, so the names can refer to the same active peptide in scientific literature. That naming relationship is useful for searching older papers, but it is not enough to authenticate a commercial product.

Online listings may use PT-141 as a familiar catalog name while omitting the complete sequence, cyclic linkage, terminal chemistry, salt or counterion description, and lot-level identity evidence. A label can be chemically plausible yet still leave the actual material unresolved.

For evidence matching, use ‘bremelanotide’ or ‘PT-141’ only when the source defines the same cyclic peptide. Do not treat melanotan II, afamelanotide, alpha-MSH, or another melanocortin agonist as interchangeable merely because it acts in the same receptor family.

Molecular identity: the cycle, termini, and acetate all matter

The current U.S. product label describes bremelanotide acetate as a synthetic cyclic heptapeptide. The structure contains an acetylated amino terminus, a lactam cycle linking the aspartic-acid and lysine residues, and a free carboxylic acid at the other terminus. Those features distinguish the molecule from a linear sequence or a differently terminated analog.

The label also reports acetate associated with the peptide and gives the molecular weight on a free-base basis. That distinction matters when a certificate lists an expected mass, assay value, or nominal vial quantity. Peptide mass, acetate contribution, water, residual solvents, and other nonpeptide material are different parts of the composition.

A mass result can support the identity of the peptide moiety, while chromatographic purity describes detected components under that method. Neither alone proves correct cyclic connectivity, absolute peptide content, finished-product equivalence, sterility, or stability.

Cell and receptor evidence: activity is broader than one target

FDA labeling describes bremelanotide as a nonselective melanocortin-receptor agonist. MC1R and MC4R binding are especially relevant at the exposure levels evaluated for the approved product, but the peptide can activate several receptor subtypes. MC1R signaling helps explain pigmentation effects, while MC4R is expressed in multiple areas of the central nervous system.

A 2021 structural study resolved bremelanotide bound to human MC4R and paired the structure with cell-based signaling assays. The work mapped ligand-receptor contacts and receptor residues involved in activation. It supplies direct molecular evidence for receptor engagement, not a complete explanation of a complex human outcome.

FDA's label states that the mechanism by which the approved product improves HSDD is unknown. Receptor binding and cAMP signaling establish pharmacology under experimental conditions; they do not prove which neural circuits, psychological processes, or contextual factors account for the clinical result.

Animal evidence: selected behaviors changed in female rats

A 2004 study examined PT-141 in hormone-primed female rats and reported increased solicitation-related behaviors in two testing environments. The effect was more apparent in appetitive or proceptive behaviors than in every measure of receptivity. The authors interpreted the findings as evidence that central melanocortin systems participate in a network related to sexual motivation.

That experiment supports a specific preclinical hypothesis. It does not establish a human diagnosis, a subjective experience, or a clinically meaningful outcome. The animals were ovariectomized, hormonally prepared, and observed in controlled behavioral chambers—conditions designed to isolate a biological signal rather than reproduce ordinary human relationships or desire.

Animal work with related melanocortin compounds also cannot be pooled automatically with bremelanotide. Sequence, receptor profile, species, hormonal state, endpoint, and experimental route all affect the interpretation.

Early human research: a signal, a tiny sample, and a different formulation

A small 2006 randomized crossover study enrolled 18 premenopausal women with sexual arousal disorder and evaluated an intranasal investigational formulation. More participants reported moderate or high desire after bremelanotide than after placebo, while the physiological measure of vaginal vasocongestion did not differ significantly. The authors presented the work as preliminary.

This study is informative because it measured subjective and physiological outcomes separately and those outcomes did not move in the same way. It also shows why an early positive signal should not be summarized as established effectiveness: the sample was very small, the diagnostic framing differed from the later approved indication, and the studied formulation was not the finished product FDA eventually approved.

Later phase 2 research used larger samples and helped select the product and outcome measures advanced into registration trials. Those results strengthened the case for phase 3 testing but remained part of a sponsor-led development program rather than independent confirmation of every possible use.

Phase 3 evidence: two positive primary endpoints and one important negative result

The RECONNECT program comprised two similarly designed, 24-week, randomized, double-blind, placebo-controlled trials. Together, the safety and efficacy program included 1,247 premenopausal women with acquired, generalized HSDD. The studies used validated patient-reported instruments to measure change in sexual desire and distress related to low desire.

In both trials, bremelanotide produced statistically significant improvement over placebo on the co-primary desire and distress measures. The direction was consistent across the two studies, which is stronger evidence than a single uncontrolled report.

The number of satisfying sexual events was a secondary endpoint. FDA labeling reports no significant between-group difference on that measure. This does not erase the positive co-primary results; it narrows what the trials established. A defensible summary states which outcomes improved and which did not rather than compressing the program into ‘increased libido’ or ‘improved sexual performance.’

How to read the magnitude and limits of the clinical result

Statistical significance shows that the observed group difference was unlikely to be explained by chance under the analysis plan. It does not tell every reader how large, noticeable, or important the average change would be for an individual. The trials relied on patient-reported scales, which were appropriate for desire and distress but require careful interpretation alongside responder analyses, discontinuations, and adverse events.

The pivotal population was specific: premenopausal women with acquired, generalized HSDD after excluding several alternative explanations for low desire. The result cannot be generalized automatically to men, postmenopausal women, people with situational concerns, or people whose low desire is associated with another condition, relationship problem, or substance.

The trials and major follow-up publications were industry sponsored, and several authors reported employment, consulting, or other relationships with the developers. Disclosure does not make the data invalid. It is a reason to examine protocol registration, prespecified endpoints, attrition, absolute effect sizes, and independent replication rather than relying on the conclusion sentence alone.

The safety record belongs to the studied product and population

The current FDA label describes transient increases in blood pressure with reductions in heart rate, focal hyperpigmentation, and nausea among the principal warnings and precautions. In the pooled phase 3 trials, nausea was the most common adverse reaction and occurred much more often with the active product than with placebo. Flushing, headache, and injection-site reactions were also reported more frequently.

These data provide a substantially stronger safety record than anecdotes or a supplier FAQ. They remain bounded by the formulation, exposure pattern, trial exclusions, follow-up, and postmarketing information associated with the approved product. They do not establish the safety of an unverified lyophilized vial or a different route, concentration, impurity profile, or pattern of exposure.

This article does not translate the label into use instructions. The label is included because it demonstrates that approval contains explicit risk information and limitations—not merely a positive efficacy decision.

FDA approval: exactly what was reviewed

FDA approved New Drug Application 210557 for Vyleesi in June 2019. The current label defines the product as a prescription bremelanotide acetate solution in a single-dose autoinjector and limits the indication to premenopausal women with acquired, generalized HSDD meeting the label's criteria. It specifically states that the product is not indicated for postmenopausal women or men and is not intended to enhance sexual performance.

That approval is product specific. FDA reviewed the application’s manufacturing information, device and formulation, nonclinical program, clinical trials, labeling, and risk-benefit evidence. The agency did not approve the molecule name as a blanket category and did not review every material sold online as PT-141.

A supplier may accurately state that an FDA-approved drug contains bremelanotide while still misleading readers if it implies that the supplier's own vial is FDA approved, equivalent to Vyleesi, or supported by the same safety and efficacy findings. The evidence bridge requires more than a shared ingredient name.

Why a research vial is not a generic version of Vyleesi

An approved generic drug requires its own regulatory pathway and evidence of pharmaceutical equivalence and bioequivalence, together with compliant manufacturing and labeling. A research-use-only vial with a COA is not an approved generic simply because the represented peptide sequence resembles the active moiety in a branded product.

The finished product is a sterile solution with defined excipients, container closure, delivery device, specifications, stability program, and manufacturing controls. A lyophilized research material is a different presentation with its own water, counterion, fill, reconstitution, contamination, aggregation, and stability questions.

This distinction does not make research material scientifically useless. It means the correct claim is narrower: lot-level testing may characterize selected attributes of that research material. It cannot import FDA approval, clinical performance, or finished-product quality.

Supplier documentation: verify the molecule before the marketing story

A defensible supplier record should identify the complete cyclic structure rather than listing only PT-141. The sequence and linkage should be consistent with bremelanotide, including the N-terminal acetyl group, D-amino-acid assignment, lactam cycle, and free carboxyl terminus. The report should also state whether results are calculated for the free base, acetate-associated material, or another form.

Identity, purity, and quantity are separate. LC-MS can support molecular identity; an HPLC area result can describe relative chromatographic components under the stated method; and a quantitative assay is needed to support peptide content. None of those measurements alone establishes sterility, endotoxin, particle burden, stability, or equivalence to the approved drug-device product.

Finally, trace the document to the offered lot. A technically plausible spectrum from an unidentified sample, a report copied across multiple batches, or a COA without a laboratory and test date cannot support current inventory.

• Complete bremelanotide structure, including cyclic linkage and terminal chemistry
• Correct stereochemistry and D-amino-acid assignment
• Free-base, acetate, and water contributions stated consistently
• Expected and observed mass matched to the represented molecular form
• Lot-specific identity and chromatographic-purity evidence
• Quantitative peptide content kept separate from HPLC area percentage
• Sterility, endotoxin, particles, or bioburden supported only when claimed
• Stability evidence matched to the material, container, and stated conditions
• No implication that an RUO vial is Vyleesi or an approved generic

What remains unresolved

The approved indication answers one defined clinical question, not every question about melanocortin signaling. The literature does not establish broad effectiveness across sexes, menopausal status, causes of low desire, other sexual-function endpoints, or unapproved formulations. The precise central mechanism linking receptor activation to the measured clinical outcomes also remains incomplete.

For research materials, public documents rarely resolve cyclic connectivity, stereochemical purity, absolute peptide content, acetate variability, water, aggregation, degradation, and microbiological attributes in one lot-linked package. Even excellent analytical documentation would establish material characteristics—not clinical equivalence or an expanded indication.

FAQ: Is PT-141 the same as bremelanotide?

PT-141 is the historical development code for bremelanotide, and the names often refer to the same cyclic peptide in scientific literature. On a commercial listing, the alias alone does not prove identity. Verify the full structure, stereochemistry, cyclic linkage, terminal groups, molecular form, and lot-specific analytical evidence.

FAQ: Is every bremelanotide product FDA approved?

No. FDA approval applies to Vyleesi under NDA 210557, including its reviewed formulation, device, manufacturing controls, labeling, indication, and population. A research vial or online PT-141 listing does not inherit that approval because it uses the same ingredient name.

FAQ: Did the phase 3 trials improve satisfying sexual events?

No significant between-group difference was found for change in satisfying sexual events, a secondary endpoint. The trials did show statistically significant improvements on the co-primary questionnaire measures of desire and distress. Both findings belong in an accurate summary.

The defensible conclusion

Bremelanotide has a mature evidence chain compared with many peptides sold online: receptor pharmacology, structural biology, animal behavior studies, exploratory human work, two registered phase 3 trials, and an FDA-approved finished product. The evidence supports a narrow clinical conclusion for that product and population, not a universal claim about desire, performance, or every PT-141-labeled material.

For due diligence, separate four records: the exact molecule, the experimental model, the approved finished product, and the supplier's current lot. FDA approval can clarify what high-quality product and clinical evidence look like; it should never be used as a shortcut around verifying the actual research material.